# US 7,608,430 B2 · Interferon-γ antagonists and therapeutic uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 7,608,430 B2
- Document ID: US7608430B2
- Status: Granted
- Kind: B2
- Application number: 11/481,614
- Filed: 2006-07-06
- Published: 2007-01-25
- Granted: 2009-10-27
- Earliest claimed: 2005-07-08
- Assignees: Regeneron Pharmaceuticals, Inc.
- Inventors: Margaret Karow; Prerna Sharma
- Web page: https://patentgrep.com/patent/US7608430B2

## CPC

- C07K 14/715: for cytokines; for lymphokines; for interferons
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Polypeptides and multimeric polypeptides capable of binding interferon γ which are useful therapeutically in methods of treating interferon γ-related conditions or diseases.

## Claims

### Claim 1

A fusion protein comprising the amino acid sequence of SEQ ID NO:7 or 9.

### Claim 2 (depends on 1)

A multimeric protein comprising two of the fusion proteins of claim 1.

### Claim 3

A fusion protein comprising the amino acid sequence of SEQ ID NO:13 or 15.

### Claim 4 (depends on 3)

A multimeric protein comprising two of the fusion proteins of claim 3.

### Claim 5

A fusion protein comprising R1,R2 and F in the N-terminus direction, and optionally a spacer sequence between R1 and R2, or R2 and F, or both,
wherein
R1 comprising amino acids 1-239 of SEQ ID NO:2;
R2 comprising amino acids 28-246 of SEQ ID NO:4, wherein cysteine 174 of SEQ ID NO:4 is optionally changed to a different amino acid; and
F is a multimerizing component selected from the group consisting of the Fc domain if IgG and a heavy chain of IgG; and
wherein said fusion protein has an IC50 of 1-5×10−10 M in inhibiting the activity of human IFNγ as measured by a luciferase assay, or a Kd of about 1×10−11 M for human IFNγ as measured by surface plasmon resonance, or both.

### Claim 6 (depends on 5)

A nucleic acid molecule encoding the fusion protein of claim 5.

### Claim 7 (depends on 6)

A vector comprising the nucleic acid molecule of claim 6.

### Claim 8 (depends on 7)

A host-vector system comprising the vector of claim 7, in a suitable host call.

### Claim 9 (depends on 8)

A method of producing a fusion polypeptide, comprising culturing the host-vector system of claim 8 under conditions suitable for expression of the protein from the host call, and recovering the polypeptide so produced.

### Claim 10 (depends on 5)

A multimeric protein comprising two of the fusion protein of claim 5.